Find disease awareness content and relevant supporting materials

The ESGO–ESTRO–ESP 2025 guideline update integrates revised FIGO staging and new evidence to guide the diagnosis, treatment, and follow-up of endometrial carcinoma. It includes multidisciplinary recommendations for surgical, adjuvant, and metastatic care, with a focus on tumour biology and patient-centered management.

The ESMO guideline offers expert recommendations for diagnosing, staging, and treating endometrial cancer. It includes risk-based treatment algorithms and guidance for advanced or recurrent disease, supporting clinical decisions across all stages of care.

Merck Inc., known as MSD outside of the United States and Canada, announced the FDA has approved Keytruda Merck’s anti-PD-1 therapy, in combination with carboplatin and paclitaxel, followed by Keytruda as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. This approval marks the third endometrial carcinoma indication and the 40th indication overall for Keytruda in the U.S.

Positive high-level results from the DUO-E Phase III trial showed Imfinzi (durvalumab) in combination with platinum-based chemotherapy followed by either Imfinzi plus Lynparza (olaparib) or Imfinzi alone as maintenance therapy both demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy alone in patients with newly diagnosed advanced or recurrent endometrial cancer

Imfinzi plus carboplatin and paclitaxel followed by Imfinzi monotherapy is FDA approved as treatment for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR)

On 27 June 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Lynparza.

Merck Inc., announced that the FDA has approved Keytruda Merck’s anti-PD-1 therapy, as a single agent for the treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.

Latest analysis of the results from the DUO-E Phase III trial showed Imfinzi (durvalumab) plus platinum-based chemotherapy followed by Imfinzi plus Lynparza (olaparib) (Lynparza and Imfinzi arm) demonstrated an improvement in multiple key secondary efficacy endpoints, particularly in patients with mismatch repair proficient (pMMR) advanced or recurrent endometrial cancer compared to chemotherapy alone

Merck Inc and Eisai announced the first presentation of investigational data from the pivotal Phase III KEYNOTE-775/Study 309 trial evaluating the combination of Keytruda (pembrolizumab), from Merck Inc, plus Lenvima (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, for the treatment of certain patients with advanced, metastatic or recurrent endometrial cancer following one prior platinum-based regimen in any setting.